Free Trial
NASDAQ:PRME

Prime Medicine Q1 2026 Earnings Results & Report

Prime Medicine logo
$4.34 +0.46 (+11.70%)
As of 12:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Prime Medicine missed analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.28 versus the -$0.24 consensus estimate, while revenue was $856 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Prime Medicine EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Prime Medicine Revenue Results

Actual Revenue
$856 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prime Medicine Q1 2026 Earnings FAQ

Prime Medicine (NASDAQ:PRME) reported earnings of -$0.28 per share for Q1 2026, missing the consensus estimate of -$0.24. The report was announced on Thursday, May 7, 2026.

Prime Medicine reported revenue of $856 thousand for Q1 2026.

Prime Medicine Earnings Headlines

Prime Medicine Q3 Loss Narrows, Revenue Rises
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NASDAQ:PRME) is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions.

The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies.

Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts. Its technology is rooted in research by geneticist David Liu and colleagues, who helped develop prime editing.

View Prime Medicine Profile